DailyIQ
Last updated 24 minutes ago

UTHR·UTHR

$.
-. (-.%)
After Hours
High
$484.98
Open
$478.90
Market Cap
20.71B
52W High
$519.99
Low
$471.00
P. Close
$566.83
P/E
16.28
52W Low
$266.98
Fwd P/E
-
Mean Target
-
Technical Score (1D)
50
NEUTRAL
News Sentiment
54
MIXED
United Therapeutics will release its Q4 and full-year 2025 financial results before market open on February 25, 2026, with a webcast scheduled for the same day. This announcement could lead to increased volatility in the stock as investors react to the company's performance and future guidance. The company's financial results will be closely watched for insights into its revenue streams and profitability. ChartMill's analysis indicates United Therapeutics meets the criteria for quality investing, demonstrating strong revenue growth and a debt-free balance sheet. This assessment suggests a positive fundamental outlook for the company, potentially attracting investors seeking stable, high-quality investments. The idiopathic pulmonary fibrosis (IPF) market is projected to reach $6.7 billion by 2035, driven by rising prevalence and novel treatments. This market expansion, with a CAGR of 9.4%, presents opportunities for companies with IPF treatments. The TETON-2 study data and new approvals are reshaping treatment paradigms, indicating potential for growth in the sector.
Earnings Summary
United Therapeutics Corporation, a biotechnology company, develops and commercializes products for chronic and life-threatening diseases, operating within the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. In the last two reported quarters, the company's revenue increased from Q4 2024 to Q4 2025, though EPS data is incomplete. The company's EPS was slightly below estimates in Q4 2024. The company's revenue growth is a positive sign, though the lack of complete data makes a full analysis difficult. Recent news highlights the company's focus on organ development and the growth potential within the idiopathic pulmonary fibrosis (IPF) market. Investors should monitor the company's advancements in organ development and any related regulatory approvals, as the company is focused on developing new organs.

EPS

EstBeatMiss
$5.96$6.45$6.95$7.44$7.93Q4'24Q4'25
QtrEstActual+/−
Q4'25$7.33$7.70+5.1%
Q4'24$6.27$6.19-1.2%

Revenue

EstBeatMiss
$722M$752M$783M$813M$843MQ4'24Q4'25
QtrEstActual+/−
Q4'25$829M$790M-4.7%
Q4'24 - $736M -

Market Data

UTHR Stock Snapshot

UTHR is currently trading at $564.89, giving UTHR a market cap of 20.71B and a P/E ratio of 16.3. Today's range spans $471.00–$484.98, with shares opening at $478.90 and moving down $1.94 (0.3%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 54/100.

Over the past year UTHR has traded between $266.98 and $519.99 - the current price is +111.6% off the 52-week low and +8.6% from the high.

Neither bulls nor bears have the upper hand on UTHR (UTHR) right now. Score: 50/100 (HOLD). Sentiment: neutral (54/100). Price: $564.89 (near 52-week highs). (P/E: 16.3) At 20.71B in Healthcare market cap, the 52-week range of $266.98–$519.99 is the relevant frame - where the stock sits within that range, and whether volume confirms any directional move, matters more than the HOLD label alone.

In neutral phases, large-cap Healthcare names like UTHR are often where sector rotation debates play out quietly — at 20.71B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 50/100 (HOLD) and neutral sentiment (54/100) at $564.89 (near 52-week highs) describe a stock that is being considered rather than avoided.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…